Coronary artery stents:

a systematic review & economic evaluation



Addendum A

Data no longer confidential





Review aims:

To assess the effectiveness and cost effectiveness of the use of coronary artery stents in patients with coronary artery disease (CAD).

Specifically the clinical review compares the use of:

- Stent versus Percutaneous Transluminal Coronary Angioplasty (PTCA)
- Stent versus Coronary Artery Bypass and Graft (CABG)
- Stent versus drug-eluting stent (DES).

The economic analysis compares the cost effectiveness of:

- Stent versus DES
- Stent versus CABG.

NHS R&D HTA Programme
The National Institute for Clinical Excellence
<i>Liverpool Reviews & Implementation Group</i> Sherrington Buildings University of Liverpool Ashton Street Liverpool, UK L69 3GE

Tel: 0151 794 5541 Fax: 0151 794 5477 Email: LRiG@liv.ac.uk

Contents:

	ndum 1 Drug-eluting stents: evaluation of clinical effectiveness including data confidential when was submitted
6.1.3	DES: Data analysis
6.2	Discussion
6.2.3	Comparability of interventions
6.2.4	Outcomes
6.2.5	Subgroups of patients
6.2.6	Data availability
6.3	Conclusions



Addendum 1

Drug-eluting stents: evaluation of clinical effectiveness including data confidential when report was submitted

Introduction

This Addendum includes data used in the evaluation of the clinical effectiveness of drugeluting stents (Chapter 6) which were considered commercial in confidence when the report was submitted. These data have since been made public and therefore the relevant text in the results, discussion and conclusion sections (6.1, 6.2, 6.3) as well as outcome tables (Table 6H) and Figures 6A-E are presented with these data reinstated.

Readers should consult this Addendum when considering the Executive Summary, Chapter 6 and the Conclusions of the report.



6.1.3 DES: Data analysis

Meta-analysis is presented for event rate, mortality, AMI, and binary restenosis. Data are pooled using a fixed effect model with odds ratio and 95 percent confidence intervals. Where qualitative heterogeneity exists, a result of the application of a random effects analysis is also presented.

It is not within the remit of this review to compare stents eluting different pharmaceutical agents. However, within the presented analyses stents loaded with related compounds are labelled and grouped for ease of reference. Three studies (ASPECT, ELUTES and SCORE) evaluated the effects of differing doses of the same agent, while TAXUS II evaluated the effects of slow and moderate drug release. For the purposes of this analysis the results from these groups have been combined. Results of the analysis are presented in forest plots Figures 6A to 6E, while details are provided here.

DES: Event rate

Analysis of event rates favours DES at 6 (OR: 0.49, 95% CI 0.38 to 0.61) and 12 months (OR: 0.37, 95% CI 0.27 to 0.50). However, in the 6 month analysis there is heterogeneity, and the analysis was re-calculated using a random effects model. This more conservative analysis shifts the OR to 0.59 (95% CI 0.31 to 1.11).

The direction and significance of this is maintained in the two year RAVEL data (OR: 0.46, 95%CI 0.22 to 0.97)

DES: Mortality

Death in all studies was a rare event. There is no evidence of a difference between the groups. Event rates in the short-term do not differ between the groups. This trend is maintained in the RAVEL 2 year data. There are five non cardiac deaths in the DES arm of RAVEL to 2 years compared to one in the non DES arm, compared to one and two cardiac deaths in each respectively.

DES: AMI

There is no evidence of a difference in incidence of AMI between DES and stents in the short-term or at six months. Data at 12 months indicates an increase in AMI in the DES group. This outcome is predominated by the outcome of the SCORE trial. Two year RAVEL data show no difference between the groups in rate of AMI.

DES: Binary restenosis

Binary restenosis (greater than 50 percent) is reported for seven of the included studies at 6 months and at 9 months for PATENTCY, SIRIUS and E-SIRIUS. Analysing these data together suggests a benefit of DES over non-eluting stents in the taxane and sirolimus groups. This advantage is not evident in the evaluation of Actinomycin in the ACTION trial.

6.2 Discussion

Drug-eluting stents represent a simple adaptation of a currently provided technology. One of the attractions therefore is that if considered effective and subject to funding, it could be easily adopted. The vast majority of interventional cardiologists are enthusiastic about the use of drug-eluting stents. However, current available data has limited follow-up and it remains to be seen whether there will be greater frequency of late thrombosis or delayed restenosis; as



with all new technology it may be expected after the initial enthusiasm to have some drawbacks.

Not all cardiologists are enthusiasts: some point to evidence from preclinical animal studies that DES can cause significant medial necrosis and persistent local fibrin deposition, suggesting delayed healing. Animal studies have also shown a reduction in restenosis with DES at one month which is lost by six months, i.e. that the effects of the DES were temporary and probably only delayed healing. By comparison with animal models, the temporal response to healing is much delayed in man, and therefore some fear that short-term reductions in restenosis may not translate into long-term gains as late restenosis becomes more common.(175) Others point out that animal models differ depending on the species studied, and that these cannot be easily translated into human biology. We need therefore to consider the long-term human studies so far reported.

First in Man was an open non-comparative study in patients with coronary heart disease treated with a single sirolimus eluting velocity stent in Brazil and the Netherlands. Twelve month follow-up has been reported for the 45 patients,(176), showing no patient reaching more than 50 percent diameter stenosis at one year based on angiography. Neo-intimal hyperplasia, as assessed by intravascular ultrasound was found to be virtually absent both at 6 and 12 months. The authors conclude that the study demonstrates a sustained suppression of neo-intimal proliferation by the DES. Two year data has also been reported for the 15 patients from the Netherlands.(177) Within the following 2 years there were no additional events in these patients except that 2 had undergone significant lesion progression in a site remote from the sirolimus eluting stent and which required further intervention. Angiography showed no significant change in the stent minimal luminal diameter or percent diameter stenosis compared to earlier angiography. In general these studies are reassuring about the long-term safety of this DES. The 2 year data from RAVEL greatly increases the information available at two years, and is similarly reassuring about the long-term safety of this device. The results in revascularisations at two years are discussed below.

6.2.3 Comparability of interventions

[No confidential data used in Report.]

6.2.4 Outcomes

The trials reported to date repeat some of the problems identified in the comparison of stents to PTCA. They identify a variety of definitions of MACE or MACCE. Therefore, the difficulties of interpreting composite endpoints remain. There are problems identifying when revascularisations in particular were clinically or angiographically driven. A standardised definition of clinically driven revascularisations is now available and was applied in many of the studies reported here. However, the definition may mislead. For instance in the nine and twelve month results of SIRIUS, we are told that the revascularisation rate represents 'clinically driven' events only, but the definition of 'clinically driven' includes a purely angiographic criterion - 'a target lesion with an in-lesion diameter stenosis greater than 70 percent in the absence of the above mentioned ischaemic signs or symptoms'. It is argued that this criterion only identifies patients who would go on to have a clinically driven procedure within a short space of time anyway. However its effects on revascularisation rates are clearly seen in the RAVEL study, where a Kaplan-Meier plot (Figure 2, page 1778 of the article) shows a clear increase in revascularisations at the time of the planned angiography. Some of this may have been because in patients with developing angina, the clinically driven intervention was delayed slightly in the knowledge that the patient was due to have an

6: Addendum A



angiography in the near future. Nevertheless, the results do suggest that the angiographic appearance had an effect on the revascularisation rate. The text describes patients either as having clinically indicated revascularisations but only in terms of angina or positive stress test, or in terms of purely angiographically driven revascularisations. It makes no clear distinction about whether any patients had revascularisation on the basis of greater than 70 percent restenosis alone. Communications with the sponsors suggests that no patients in fact had revascularisations for this indication only.

A point of note is the rate of revascularisation in the control arms of this and the SIRIUS study. The SIRIUS trial, in long lesions, reports broadly similar event rates in the control arm at 12 months (22.3 percent) to RAVEL at twelve months (22 percent in the control group) The PRESTO study is quoted in the BCIS submission,(178) as an example of likely revascularisation rates in clinical practice; it randomised 11,484 patients to either systemic immune suppression using Tranilast or to placebo before PTCA, which involved stenting in 83 percent of cases. The primary endpoint was death, myocardial infarction or ischemia-driven target vessel revascularisation: only a subgroup of 20 percent of patients had protocol driven angiograms. This combined event measure occurred in 15.8 percent in the placebo group and a similar number of the treated group at 12 months, and Tranilast was therefore unsuccessful.

This rate of events is substantially less than reported in the control arms of RAVEL or SIRIUS. This maybe an artefact, reflecting the patient selection for these trials with either relatively small (RAVEL) or small and long lesions both of which would carry a higher rate of restenosis than might have been seen in the less selected patients in PRESTO. It is claimed by the authors of the RAVEL(119) study that the higher restenosis rates in RAVEL was in keeping with a linear regression model derived from the BENESTENT(39) studies. But part of the difference might also lie in revascularisations being in part angiographically driven in RAVEL and SIRIUS.

In a PRESTO subgroup (about 20 percent of the total) studied by angiography, there was an association between restenosis and major adverse coronary events. In patients with no restenosis, 5 percent had MACE and 95 percent did not; in patients with restenosis 46 percent had MACE, 54 percent did not. This and other studies show a clear link between angiographic appearance and clinical event rates, although it is difficult to quantify this directly. The BCIS submission to NICE suggests approximately half of angiographically indicated revascularisations also being clinically indicated. However, in the nine month data from SIRIUS, the number of clinically driven TLRs is quoted as 4.1 percent in the DES arm and 16.6 percent in the non-DES arm and a rate of angiography driven revascularisations of 1.9 percent in the DES arm and 4.0 percent in the DES arm. So here we have between 70 percent and 80 percent of TLR 'clinically driven' as defined by the trial, rather than 50 percent typically suggested by cardiologists. Given the criteria for 'clinically driven revascularisations' in this study cited above, this high ratio of angiographic to clinically driven revascularisations and probably no different to those in other studies.

The 2 year data from RAVEL provides further information on this aspect: there were no further angiographic follow-up in the 12-24 month period and so any further revascularisations may be more confidently attributed to clinical need. In the control arm, there were 16/118 clinically driven revascularisations by 12 months, and no further revascularisations by 24 months. In the DES arm, there was one clinically driven revascularisation by twelve months and a further 2 (total 3/120) by 24 months. The absolute

7: Addendum A



benefit is therefore 11.1% at two years. This suggests neither a major loss of effect of the DES due to delayed restenosis nor any additional benefit over the second twelve months. Longer-term follow-up is still desirable.

6.2.5 Subgroups of patients

Studies included in the review were not powered to assess effectiveness in subgroups of patients and therefore analysis of data by subgroup must be interpreted very cautiously. Key subgroups would be diabetics, patients with small vessels or long lesions, and LAD lesions.

Some preliminary results from SIRIUS have been reported to the review team in confidence: of the 1058 patients randomised, 279 had diabetes. For those people with diabetes, the TLR rates at 12 months were 8.4% in Sirolimus DES group versus 26.4% in the control group. MACE rates were 11.5% in Sirolimus DES group versus 29.1% in control the control group - a relative reduction by 60%, in keeping with the proportional reduction in the study as whole.

The RAVEL study also included a subgroup of diabetics but to date the only comment on outcomes in them is that the benefits seen overall were similar in diabetics and non-diabetics but whether this is in proportions of patients with restenosis or in the extent of restenosis is unclear. Some results from a diabetic subgroup in RAVEL are quoted in the BCIS submission to NICE, although a reference is not given nor are these data found in the publication to date.

Inclusion criteria for five of the included studies (ASPECT, ELUTES, RAVEL, SIRIUS and E-SIRIUS) indicated that they would include patients with vessel diameter less than 3.0 mm (small vessel). Presentation of the data did not allow for assessment of outcomes related to vessel size.

Other subgroups reported in SIRIUS, so far only in conferences, are those for lesions of the left anterior descending artery (LAD), another high-risk group. Here, the TLR on Sirolimus was 5.1 percent versus 19.7 percent in the control group, and the MACE rates were 8.5 percent on Sirolimus versus 22.5 percent on percent.

Patients experiencing AMI were excluded from studies of DES and therefore results cannot be generalised to this population.

So far therefore, data on subgroups is limited and should not be overstated. What limited data there is indicates that the relative benefits of drug-eluting stents are maintained in high-risk subgroups of diabetics and those with small vessels. Given the higher background risk of these patients, maintaining the proportionate benefits would lead to a greater absolute benefit and this may provide useful pointers in targeting DES. This is discussed in greater detail in Chapters 9 and 11 of this report.

6.2.6 Data availability

[No confidential data used in Report.]

6.3 Conclusions

The available data do not allow for any conclusions to be made with regard to the effect of drug-eluting stents on mortality or in the case of AMI.

Overall, the results indicate that the drug-eluting stents decrease rates of restenosis and therefore revascularisation following placement. The exact rate of lowering of 8: Addendum A *LRiG*



revascularisations seems to be by approximately 60 to 70 percent at 12 months, but there are difficulties in definitions of how many of these were clinically driven. Outcomes from one study indicate that this benefit is largely maintained over two years. However, we stress that these results are interim and incomplete, and we await definitive publication of studies confirming patient numbers and outcome.



Study name	Intervention	Event Rate (%)	Mortality (%)	Any MI (%)	Revascularisation (%)	CABG (%)	PCI (%)	BBR (%)
E-SIRIUS ^E Formerly CIC	<u>Stent</u> <u>177</u>	<u>9 months 22.6</u>			TVR Free 9 months 76.9 TLR Free 9 9 months 78.3			<u>8 months:</u> 65/154 42.2
	<u>DES</u> <u>175</u>	<u>9 months 8.0</u>			TVR Free 9 months 76.9 TLR Free 9 9 months 95.9			<u>8 months:</u> 6/151 4.0
RAVEL ^E	Stent 118	1 year 28.8	In Hosp 0.0 1 year 1.7	In Hospital 2.5 1 year 4.2	TVR (not TL) 1year 1.7 TLR (all) 1year 23.7	In Hosp 0.0 1year 0.8	TLR 1 year 22.9	6 months 26.6 (In stent, n unclear)
	DES 120	1 year 5.8	In Hosp 0.0 1 year 1.7	In Hospital 2.5 1 year 3.3	TVR (not TL) 1year 0.8 TLR (all) 1year 0.8	In Hosp 0.0 1 year 0.8	TLR 1 year 0.0	6 months 0.0 (In stent, n unclear)
RAVEL ^G Formerly CIC	<u>Stent</u> <u>118</u>	<u>2 years 19.5</u>	<u>2 years 2.5</u>	<u>1 year ^F (7/118) 5.9</u> 2 years 5.1	<u>TVR (not TL)</u> 2 years 2.5 <u>TLR (all)</u> 2 years 13.6	<u>2 years 0.0</u>	<u>TLR</u> 2 years 13.6	<u>6 months</u> 28/107 26.6
	<u>DES</u> 120	<u>2 years 10.0</u>	<u>2 years 5.0</u>	<u>1 year^F (4/120) 3.3</u> 2 years 4.2	<u>TVR (not TL)</u> 2 years 0.8 TLR (all) 2 years 2.5	<u>2 years 0.8</u>	<u>TLR</u> 2 years 1.7	<u>6 months</u> <u>0/105 0.0</u>

Table 6H DES: Outcomes



LRiG

Study name	Intervention	Event Rate (%)	Mortality (%))	Any MI (%)		Revascularisat (%)		CABG (%)	PCI (%)	BBR (%)
SIRIUS	Stent 525	In hospital 9 months		In hospital 9 months			1.5 3.2	<i>TVR (non-TL)</i> In-hospital 9 month TLR: 30 day 9 month		30 days 0% blinded data	30 days 0% blinded data	8 month In-segment: 36.3 8 month In-stent: 35.4 (n=353)
	DES 533	In hospital 9 months		In hospital 9 months			2.3 2.8	<i>TVR (non-TL)</i> In-hospital 9 month TLR: 30 day 9 months	0.0 3.2 0.2 4.1			8 month In-segment: 8.9 8 month In-stent: 3.2 (n=348)
<u>SIRIUS</u> Formerly CIC	<u>Stent</u> <u>525</u>	<u>1 year</u>	22.3	<u>1 year</u>	<u>0.8</u>	<u>1 year</u> :	<u>3.4</u>	TĹR	<u>6.7</u> 20.0	<u>9 mo CABG (Target Lesion) 8/525</u> <u>TVR+TLR</u> <u>1 year 3.0</u>	9mo PTCA (Target lesion): 83/525 TVR+TLR 1 year 24.8	
	<u>DES</u> 533	<u>1 year</u>	8.3	1 year	<u>1.3</u>	<u>1 year</u> :	<u>3.0</u>	<u>TVR (non-TLR)</u> 1 year <u>TLR</u> 1 year		<u>9 mo CABG (Target Lesion) 3/533</u> <u>TVR+TLR</u> <u>1 year 1.5</u>	<u>9mo PTCA (Target lesion): 20/533 TVR+TLR 1 year 7.5</u>	



Study name	Intervention	Event Rate ((%)	Mortality (%	⁄o)	Any MI (%)		Revascularisa (%)		CABG (%)	PCI (%)		BBR (%)
	Stent 30	30 days 6 months 12 month	0.0 6.6 10.0	30 days 12 months	0.0 0.0	12 months	0.0	30 day TLR 6 month 1 year TVR-non TLR 1 year		6 months 12 months		TLR (PCI) 6 months 6 months Non-TLR (PCI) 1 year 1 year	6.6 10 0.0 0	6 months (n=29)10.3
	DES 31 (30)	30 days 6 months 12 months		30 days 12 months	0.0 0.0	12 months		30 day TLR 6 month 1 year (n=30) TVR-non TLR 1 year (n=30)		6 months 12 months		TLR (PCI) 6 months 1 year Non-TLR (PCI) 6 months 1 year	0 0 3 3	6 months (n=30) 0.0
TAXUS I Formerly CIC (Confidential information indicates denominator)	<u>Stent</u>							TVR (non-TLR)	<u>2/30</u> 3/30	<u>1 year</u>	1/30			
	DES							<u>TLR</u> <u>1 year (</u> TVR (non-TLR)	0/31 0/31) 1/31	<u>1 year</u>	0/31			

Study name	Intervention	Event Rate (%)	Mortality (%)	Any MI (%)	Revascularisation (%)	CABG (%)	PCI (%)	BBR (%)
TAXUS II	Stent 270	30 day (n=272) 4.4 6 month 19.3	6 month 0.4	6 month 5.2	TVR 6 month 13.0 TLR: 6 month 15.5	6 month 0.7		Stented segment: 6 months 19.0 (n=263)
	DES 266	30 day 2.3 6 month 7.9	6 month 0.0	6 month 1.9	TVR: 6 month 6.8 TLR 6 month 3.7	6 month 0.7		Stented segment: 6 months 3.5 (n=256) Slow-DES: 2.3 (n=128) Mod-DES 4.7 (n=128) 4.7 4.7
TAXUS II- Formerly CIC	<u>Stent</u>	<u>30d: 12/270</u> 6mo: 52/263	<u>6mo 0.6</u>	<u>6mo (Q and non Q) St</u> <u>comb 14/263, DES</u> <u>comb 5/259</u>	6mo: TVR: 42/263 6mo TLR 35/263	<u>6mo: St comb 2/263,</u>		<u>Analysis segment:</u> 6 months 22.0 (n=264)
	DES	<u>30d: 6/266</u> <u>6mo 21/259</u>	<u>6 mo_0.0</u>		<u>6mo: TVR 8/259</u> 6mo TLR: 10/259	<u>6 mo: DES comb</u> <u>2/259</u>		Analysis segment: 6 months 7.0 (n=256) 5.5 Slow-DES: 5.5 (n=128) 8.6 (n=128) 128

B TAXUS I TLR one person had PTCA then CABG at 198 days, E: combined clinically driven and angiographically driven data, as presented in (119); F: Data for MI as reported in Submission to NICE, G Only clinically driven events are reported



LRiG

Figure 6A DES: Meta-analysis of event rate

Comparis Outcome:		Rate: up to 36 day	\$				
		DES	Stents	OR	Weight	OR	
Study		n/N	n/N	(95%Cl Fixed)	%	(95%CI Fixed)	
01 Taxane DE ASPECT	s		4.150			1 0010 51 01 55	
DELIVER		8 / 118 6 / 524	1/59 2/519		\rightarrow 4.9 \rightarrow 7.8	4.22[0.51,34.55] 2.99[0.60,14.90]	
ELUTES		3/152	1/38	· •	6.1	0.74[0.08,7.37]	
× PATENTC × TAXUSI	(0/24 0/31	0/26 0/30		0.0 0.0	Not Estimable Not Estimable	
X TAXUST TAXUST		6/266	12/272		45.4	0.50[0.18,1.35]	
Subtotal(95%		23/1115	16/944		64.1	1.11[0.57,2.16]	
Test for heter	ogeneity chi-sq all effect z=0.30	uare=5.60 df=3 p=0.13					
Test for over	an en eu z-0.30	ο μ=0.0					
02 Rapamyci	DES						
× FUTURE SIRIUS		0/24 13/533	0/12 8/525	_	0.0 30.8	Not Estimable 1.62[0.66,3.93]	
Subtotal(95%	CI)	13/557	8/537		30.8	1.62[0.66,3.93]	
Test for heter	ogeneity chi-sq	uare=0.00 df=0 p<0.00					
Test for over	all effect z=1.06	6 p=0.3					
03 Actinomyc	in DES						
ACTION		5/241	1/119		→ 5.1	2.50[0.29,21.64]	
Subtotal(95%	Cl) ogeneity chi-sq	5 / 241	1/119		▶ 5.1	2.50[0.29,21.64]	
	all effect z=0.8						
Total(95%Cl)		41 / 1913	25/1600		100.0	1.34[0.80,2.24]	
	ogeneity chi-sq	uare=6.62 df=5 p=0.25			100.0	10 (0.00)22 (]	
Test for over	all effect z=1.10	0 p=0.3					
-				.1 2 1	5 10		
Comparis	on: Event	Rate		Favours DES Favo	urs Stent		
Outcome:		Rate: 6 months					
Study		DES n/N	Stents n/N	OR (95%Cl Fixed)	Weight %	OR (95%Cl Fixed)	
	-			(second lace)	78		
01 Taxane DE ASPECT	3	12/118	3/59		1.8	2.11[0.57,7.80]	
ELUTES		9/152	4/38		3.0	0.53[0.16,1.84]	
PATENTC	′ (9 months)	3/24	6/26		2.5	0.48[0.10,2.17]	
TAXUS I TAXUS II		0/31 21/266	2/30 52/270		1.2 23.3	0.18[0.01,3.93] 0.36[0.21,0.62]	
Subtotal(95%	CI)	45 / 591	67 / 423	-	31.7	0.48[0.31,0.72]	
		uare=6.46 df=4 p=0.17					
Test for over	all effect z=-3.5	0 p=0.0005					
02 Rapamyci	DES (9 month)						
E-SIRIUS '	CIC*	14/175	40/177		17.9	0.30[0.16,0.57]	
SIRIUS Subtotal(95%	n	38 / 533 52 / 708	99 / 525 139 / 702		45.4 63.3	0.33[0.22,0.49] 0.32[0.23,0.45]	
		uare=0.07 df=1 p=0.79		-	00.0	0.02[0.20]0.40]	
Test for over	all effect z=-6.5	9 p<0.00001					
03 Actinomyo	in DES						
ACTION		56 / 241	9/88	_ _	5.0	2.66[1.25,5.63]	
Subtotal(95%		56 / 241	9/88		- 5.0	2.66[1.25,5.63]	
	all effect z=2.5%	uare=0.00 df=0 p<0.00 5 p=0.01	501				
Total(95%Cl)		153/1540	215/1213	•	100.0	0.49[0.38,0.61]	
Test for heter		uare=31.95 df=7 p<0.0		•			
Test for over	all effect z=-6.0	l5 p≺0.00001					
				.1 .2 1 Favours DES Favou	5 10 Storts		
Comparis					rs Stents		
Outcome:		Rate: 12 months DES	Stents	OR	\$47-1-L-1	OR	
Study		n/N	n/N	(95%CI Fixed)	Weight %	(95%Cl Fixed)	
01 Taxane Di	s						
ASPECT		17/118	6/58	_ 	4.6	1.46[0.54,3.92]	
ELUTES TAXUS I .		15/152	7/38	, +	6.7	0.48[0.18,1.29]	
TAXUST. Subtotal(95%	CI)	1 / 31 33 / 301	3/30 16/126		2.0 13.3	0.30[0.03,3.06] 0.79[0.42,1.52]	
Test for heter	ogeneity chi-sq	uare=3.10 df=2 p=0.21			.0.0	=.	
Test for over	all effect z=-0.7	0 p=0.5					
02 Rapamyci	DES						
RAVEL		7/120	23/118	-	14.6	0.26[0.11,0.62]	
SIRIUS *CI		44 / 533	117/525 140/643		72.1	0.31[0.22,0.45]	
Subtotal(95% Test for heter		51 / 653 uare=0.17 df=1 p=0.68		•	86.7	0.30[0.22,0.43]	
	all effect z=-6.8						
Total(95%Cl)		84 / 954	156 / 769	➡	100.0	0.37[0.27,0.50]	
Test for heter		uare=9.14 df=4 p=0.05					
Test for over	all effect z=-6.6	i2 p<0.00001					
				.1 .2 1 Favours DES Favou	5 10 rs Stents		
Comparis							
Outcome:		Rate: 2 years	64 ·			AB	
Study		DES n/N	Stents n/N	OR (95%Cl Fixed)	Weight %	OR (95%Cl Fixed)	
	DES			,,			
02 Rapamycir RAVEL *C		12/120	23/118		100.0	0.46[0.22,0.97]	
Subtotal(95%	CI)	12/120	23/118		100.0	0.46[0.22,0.97]	
	ogeneity chi-sq						
rest for over	Il effect z=-2.0	5 p=0.04					
Total(95%Cl) Test for beter	napatu chi c	12/120	23/118		100.0	0.46[0.22,0.97]	
	ogeneity chi-sq ill effect z=-2.0						
					1		
				.1 .2 1 Favours DES Favou	5 10 rs Stents		

CIC Information *formerly* Commercial in Confidence. RAVEL 12 month event rate data are clinically driven.



Figure 6B DES: Meta-analysis of mortality

Comparison: Outcome: Study	Mortality				
	Mortality: up to 36 days				
Study	DES	Stents	OR	Weight	OR
···•	n/N	n/N	(95%CI Fixed)	%	(95%Cl Fixed)
01 Taxane DES					
ASPECT	1 / 118	0/59	←	→ 14.8	1.52[0.06,37.86]
DELIVER	1/517	1/512	·	→ 22.6	0.99[0.06,15.88]
ELUTES	1 / 152	0/38		→ 17.8	0.76[0.03,19.08]
× PATENTCY × TAXUSI	0 / 24 0 / 31	0/26 0/30		0.0 0.0	Not Estimable Not Estimable
TAXUST	0/266	1/270		. 33.5	0.34[0.01,8.31]
Subtotal(95%Cl)	3/1108	2/935		88.7	0.79[0.18,3.43]
	neity chi-square=0.46 df=3 p=0.9				
Test for overall ef	fect z=-0.32 p=0.7				
02 Rapamycin DES		0.440			Mat Falls and
× FUTURE × RAVEL	0 / 24 0 / 120	0/12 0/118		0.0 0.0	Not Estimable Not Estimable
SIRIUS	1 / 533	0/525		→ 11.3	2.96[0.12,72.84]
Subtotal(95%CI)	1 / 677	0/655	_	▶ 11.3	2.96[0.12,72.84]
	neity chi-square=0.00 df=0 p<0.0				
Test for overall ef	fect z=0.66 p=0.5				
03 Actinomycin Dł					
× ACTION Subtotal(95%CI)	0 / 239 0 / 239	0/121 0/121		0.0 0.0	Not Estimable Not Estimable
	neitychi-square=0.0 df=0	07121		0.0	NULESUNADIE
Test for overall ef					
	1001 2 0.0 p 1				
Total(95%Cl)	4 / 2024	2/1711		100.0	1.03[0.28,3.82]
	heity chi-square=0.97 df=4 p=0.9	1			
Test for overall ef	tect z=0.05 p=1				
			.1 .2 . 1 . 5	10	
~ ·	N . 19		Favours DES Favours Ster	ts	
Comparison:	Mortality Mortality 6 months				
Outcome:	Mortality: 6 months DES	Stents	OR	Weight	OR
Study	n/N	n/N	(95%Cl Fixed)	weight %	(95%Cl Fixed)
			· · ·		
01 Taxane DES ASPECT	1 / 118	0/59	_	→ 4.5	1.52[0.06,37.86]
DELIVER (9 mc		6/512	·	→ 4.5 41.2	1.52[0.05,37.86] 0.82[0.25,2.72]
ELUTES	1/152	0/38		+1.2 → 5.4	0.02[0.25,2.72] 0.76[0.03,19.08]
PATENTCY (9		1/26	· · ·	- 9.7	0.35[0.01,8.93]
SCORE	5/128	0/138		→ 3.2	12.34[0.68,225.38]
× TAXUS I	0/31	0/30		0.0	Not Estimable
TAXUS II	0 / 266	1 / 270	· · ·	10.3	0.34[0.01,8.31]
Subtotal(95%Cl)	12/1236	8/1073		74.3	1.22[0.55,2.74]
	heity chi-square=4.15 df=5 p=0.5 fect z=0.49 p=0.6	3			
rest for overall er	ieur 2-0.43 p-0.0				
02 Rapamycin DES	S (9 month)				
SIRIUS	5/533	3/525		20.7	1.65[0.39,6.93]
Subtotal(95%Cl)	5 / 533	3/525		20.7	1.65[0.39,6.93]
	neity chi-square=0.00 df=0 p<0.0	0001			
lest for overall ef	fect z=0.68 p=0.5				
03 Actinomycin Dł	5				
ACTION	1 / 241	0/88	<u></u>	→ 5.0	1.10[0.04,27.35]
Subtotal(95%Cl)	1 / 241	0/88	•	5.0	1.10[0.04,27.35]
Test for heteroger	neity chi-square=0.00 df=0 p<0.0	0001			
Test for overall ef	fect z=0.06 p=1				
Total(95%Cl)	18/2010	11/1686		100.0	1.31[0.66,2.59]
	neity chi-square=4.42 df=7 p=0.7			100.0	101[030]230]
	fect z=0.76 p=0.4				
	fect z=0.76 p=0.4			10	
	fect z=0.76 p=0.4		.1 .2 1 5 FavoursDES Favours Ster	10 ts	
Test for overall ef	Mortality		.1 .2 1 .5 FavoursDES Favours Sten	10 ts	
Test for overall ef	Mortality Mortality: 12 months		FavoursDES Favours Sten	ts	
Test for overall of Comparison: Outcome:	Mortality Mortality: 12 months DES	Stents	FavoursDES Favours Sten	ts Weight	OR (45%C) Fived)
Test for overall of Comparison: Outcome: Study	Mortality Mortality: 12 months	Stents n/N	FavoursDES Favours Sten	ts	OR (95%Cl Fixed)
Test for overall of Comparison: Outcome: Study 01 Taxane DES	Mortality Mortality: 12 months DES n/N	n/N	FavoursDES Favours Sten	ts Weight %	(95%Cl Fixed)
Test for overall of Comparison: Outcome: Study 01 Taxane DES ASPECT	Mortality Mortality: 12 months DES nN 1/118	n/N 0/58	FavoursDES Favours Sten	ts Weight % → 8.4	(95%CI Fixed)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES	Mortality Mortality: 12 months DES nN 1/118 1/152	n/N 0 / 58 0 / 38	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0	(95%Cl Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08]
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE	Mortality Mortality: 12 months DES n.N 1/118 1/152 5/128	0/58 0/38 0/138	FavoursDES Favours Sten	Weight % → 8.4 → 10.0 → 5.9	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 12.34(0.68,225.38)
Test for overall of Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE × TAXUS I	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30	n/N 0/58 0/38 0/138 0/30	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable
Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI)	Mortality Mortality: 12 months DES n.N 1/118 1/152 5/128 0/30 7/428	n/N 0/58 0/38 0/138 0/30 0/30 0/264	FavoursDES Favours Sten	Weight % → 8.4 → 10.0 → 5.9	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 12.34(0.68,225.38)
Test for overall of Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtotal(95%CI) Test for heteroger	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30	n/N 0/58 0/38 0/138 0/30 0/30 0/264	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable
Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI) Test for heteroger	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30 7/428 refly chi-squee7 =91 df-2 p=0.3	n/N 0/58 0/38 0/138 0/30 0/264	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable
Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(35%CI) Test for heteroger Test for overall ef 02 Rapamycin DES	Mortality Mortality: 12 months DES n.N 1/118 1/152 5/128 0/30 7/428 refty chi-square-191 df=2 p=0.3 fect z=1.56 p=0.12	0/58 0/38 0/138 0/30 0/264 8	FavoursDES Favours Sten	Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 1.2.34(0.69,225.38) Not Estimable 3.81(0.71,20.38)
Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI) Test for heteroger Test for overail ef 02 Rapamycin DES RAVEL	Mortality Mortality: 12 months DES n.N 1/118 1/152 5/128 0/30 7/428 etly chi-square=1.91 df-2 p=0.3 rect z=1.56 p=0.12 s 2/120	n/N 0/58 0/38 0/138 0/264 8 2/118	FavoursDES Favours Sten	Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2	(95%CI Fixed) 1 49(0.06;37 23) 0.76(0.03;19.06] 12.34(0.68,225 38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10)
Test for overall ef Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%C)) Test for heteroger Test for overall ef 02 Rapemycin DES RAVEL SIRUS *CC*	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 netly chi-squee ⁻¹ ,91 df<2 p=0.3 rect z=1.56 p=0.12 S 2/120 7/533	n/N 0 / 58 0 / 38 0 / 138 0 / 30 0 / 264 8 2 / 118 4 / 525	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0 ↓ 24.3 25.2 50.5	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.06] 12.34[0.68,225.38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56]
Comparison: Outcome: Study DI Taxane DES ASPECT ELLITES SCORE X TAXUS I Subtota(95%CI) Test for heteroger Test for overail ef 22 Rapamycin DES RAVEL SIRIUS*CIC* Subtota(95%CI)	Mortality: 12 months DES nN 1 / 118 1 / 152 5 / 128 0 / 30 7 / 428 Hetty chi-square=1.91 df=2 p=0.3 tett z=1.56 p=0.12 5 2 / 120 7 / 533 9 / 653	n/N 0 / 58 0 / 38 0 / 138 0 / 264 8 2 / 118 4 / 525 6 / 5643	FavoursDES Favours Sten	Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2	(95%CI Fixed) 1 49(0.06;37 23) 0.76(0.03;19.06] 12.34(0.68,225 38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10)
Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%C) Test for heteroger Test for overall ef 22 Rapamycin DES RAVEL SIRIUS *CIC* Subtota(95%C) Test for heteroger Est for heteroger	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30 7/428 ety chi-squere=191 df=2 p=0.3 tect z=1.56 p=0.12 5 2/120 7/533 9/653 ety chi-squere=0.23 df=1 p=0.6	n/N 0 / 58 0 / 38 0 / 138 0 / 264 8 2 / 118 4 / 525 6 / 5643	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0 ↓ 24.3 25.2 50.5	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.06] 12.34[0.68,225.38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56]
Test for overall ef Comparison: Outcome: Study 11 Taxene DES ASPECT ELUTES SCORE 12 TAXDISI Subtra (SSK-CI) 22 Repartyoin DES PAVEL SIRUS *CIC* SIRUS *CIC* SIRU	Mortality: 12 months DES nN 1 / 118 1 / 152 5 / 128 0 / 30 7 / 428 Hetty chi-square=1.91 df=2 p=0.3 tett z=1.56 p=0.12 5 2 / 120 7 / 533 9 / 653	n/N 0 / 58 0 / 38 0 / 138 0 / 264 8 2 / 118 4 / 525 6 / 5643	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0 ↓ 24.3 25.2 50.5	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.06] 12.34[0.68,225.38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56]
Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%C) Test for heteroger Test for overall ef 22 Rapamycin DES RAVEL SIRIUS *CIC* Subtota(95%C) Test for heteroger Est for heteroger	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30 7/428 ety chi-squere=191 df=2 p=0.3 tect z=1.56 p=0.12 5 2/120 7/533 9/653 ety chi-squere=0.23 df=1 p=0.6	n/N 0 / 58 0 / 38 0 / 138 0 / 264 8 2 / 118 4 / 525 6 / 5643	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0 ↓ 24.3 25.2 50.5	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.06] 12.34[0.68,225.38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56]
Test for overall of Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE < TAXUS I Subtotal(95%C)) Test for heteroger fest for overall of D2 Rapamycin DES RAVEL SIRUS *CC* Subtotal(95%C) Test for heteroger fest for overall of	Mortality Mortality: 12 months DES n/N 1/118 1/152 5/128 0/30 7/428 ety chi-squere=191 df=2 p=0.3 tect z=1.56 p=0.12 5 2/120 7/533 9/653 ety chi-squere=0.23 df=1 p=0.6	n/N 0 / 58 0 / 38 0 / 138 0 / 264 8 2 / 118 4 / 525 6 / 5643	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 → 5.9 0.0 ↓ 24.3 25.2 50.5	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.06] 12.34[0.68,225.38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56]
Test for overall of Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota((95%CI)) Test for heteroger Test for overall of SURIUS *CIC* SURIUS *CIC	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 netly chi-square=31 df<2 p=0.3 r/428 2/120 7/533 9/653 setly chi-square=0.23 df<1 p=0.6 fect z=0.74 p=0.5	n/N 0/58 0/38 0/138 0/30 0/264 8 2/118 4/525 6/643 3 3	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 5.9 0.0 ↓ 24.3 25.2 50.5 75.7	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08] 12.34[0.68,225.36] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.36] 1.48[0.52,4.19]
Test for overall ef Comparison: Outcome: Study 11 Taxane DES ASPECT ELUTES SCORE 21 TAXISI SCORE 21 TAXISI SCORE 21 Apamyoin DES PAVEL SIRUS *CIC* SIRUS *CIC*	Mortality Mortality: 12 months presson 1 / 118 1 / 152 5 / 128 0 / 30 7 / 428 1 / 152 5 / 128 0 / 30 7 / 428 1 / 162 p=0.3 retert z=1.56 p=0.12 5 2 / 120 7 / 533 9 / 653 16 / 1081	n/N 0/58 0/38 0/138 0/30 0/264 8 2/118 4/525 6/643 3 3	FavoursDES Favours Sten	ts Weight % → 8.4 → 10.0 5.9 0.0 ↓ 24.3 25.2 50.5 75.7	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08] 12.34[0.68,225.36] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.36] 1.48[0.52,4.19]
Test for overall of Comparison: Outcome: Study 11 Taxane DES ASPECT ELUTES SCORE < TAXUS I Subtotal(95%CI) Test for heteroger fest for overall of SIRIUS *CIC* SUBtotal(95%CI) Test for heteroger Fotal(95%CI)	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 netly chi-square=31 df<2 p=0.3 r/428 2/120 7/533 9/653 setly chi-square=0.23 df<1 p=0.6 fect z=0.74 p=0.5	n/N 0/58 0/38 0/138 0/30 0/264 8 2/118 4/525 6/643 3 3	Favours DES Favours Ster	Weight % → 8.4 → 10.0 → 5.9 0.0 > 24.3 25.2 50.5 75.7 100.0	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08] 12.34[0.68,225.36] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.36] 1.48[0.52,4.19]
Test for overall of Comparison: Outcome: Study D1 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%CI) Test for heteroger Test for overall of SURIUS *CIC* SURIUS *CIC* SURIUS *CIC* SURIUS *CIC* Total(95%CI) Test for overall of Total(95%CI) Test for overall of Total(95%CI) Test for overall of Total(95%CI)	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 etty chi-square=31 df<2 p=0.3 r/428 2/120 7/533 9/653 etty chi-square=0.23 df<1 p=0.6 fect z=0.74 p=0.5	n/N 0/58 0/38 0/138 0/30 0/264 8 2/118 4/525 6/643 3 3	FavoursDES Favours Sten	ts Weight $\frac{9}{9}$ → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 100.0	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08] 12.34[0.68,225.36] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.36] 1.48[0.52,4.19]
Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtota(95%C1) Test for heteroger Test for overail ef 02 Rapamycin DES RAVEL SIRUS *CC* Subtota(95%C1) Test for heteroger Test for overail ef Total(95%C1)	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 redy chi-square=1.91 df=2 p=0.3 redy chi-square=1.91 df=2 p=0.3 redy chi-square=0.23 df=1 p=0.6 redy chi-square=0.23 df=1 p=0.6 redy chi-square=2.47 df=4 p=0.6 redy chi-square=0.10	n/N 0/58 0/38 0/138 0/30 0/264 8 2/118 4/525 6/643 3 3	Favours DES Favours Ster	ts Weight $\frac{9}{9}$ → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 100.0	(95%CI Fixed) 1.49[0.06,37.23] 0.76[0.03,19.08] 12.34[0.68,225.36] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.36] 1.48[0.52,4.19]
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotal(95%CI) Test for heteroger Test for overall ef 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotal(95%CI) Test for heteroger	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 0/30 7/428 13 df-2 p=0.3 refet z=1.56 p=0.12 3 2/120 7/533 9/653 refet z=0.74 p=0.5 refet z=0.74 p=0.5 refet z=1.63 p=0.10 Mortality Mortality Z Years	nN 0 / 58 0 / 38 0 / 38 0 / 30 0 / 264 8 2 / 118 4 / 525 6 / 643 3 5	Favours DES Favours Ster	ts Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 ts	(95%CI Fixed) 1.49[0.06,37.23] 0.79[0.03,19.06] 12.34[0.68,225,38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56] 1.48[0.52,4.19] 2.05[0.87,4.84]
Test for overall ef Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%CI) Test for heteroger Test for overall ef Total(95%CI) Test for heteroger Test for overall ef Total(95%CI) Test for heteroger Test for overall ef Comparison: Outcome:	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 ety chi-square=0.3 9 (653 9 (653))))))))))))))))))))))))))))))))))))	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 0 / 200 2 / 118 4 / 525 6 / 643 5 6 / 907 5 Stents	Favours DES Favours Ster	ts Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 to ts Weight	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 1.2.34(0.69,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) OR
Test for overall ef Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE X TAXUS I SUbtota(95%C1) Test for heteroger Test for overall ef O2 Rapamycin DES RAVEL SIRIUS *CIC* SUbtota(95%C1) Test for heteroger Test for overall ef Total(95%C1) Test for heteroger Test for overall ef Comparison: Outcome: Study	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 rety chi-square=131 df=2 p=0.3 fect z=1.56 p=0.12 5 2/120 7/533 9/653 9	nN 0 / 58 0 / 38 0 / 38 0 / 30 0 / 264 8 2 / 118 4 / 525 6 / 643 3 5	Favours DES Favours Ster	ts Weight % → 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 ts	(95%CI Fixed) 1.49[0.06,37.23] 0.79[0.03,19.06] 12.34[0.68,225,38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56] 1.48[0.52,4.19] 2.05[0.87,4.84]
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtrat(65%C) Test for heteroger Test for overall ef 02 Rapamycin DES RAVEL SIRUS YCIC* Subtrat(95%C) Test for heteroger Test for overall ef Total(95%C) Test for heteroger Test for overall ef Comparison: Outcome: Study 02 Rapamycin DES	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 weby chi-square=31 df<2 p=0.3 retz z=1.56 p=0.12 c 2/120 7/533 9/653 2/120 7/533 9/653 sety chi-square=0.23 df<1 p=0.6 fect z=0.74 p=0.5 tect z=1.63 p=0.10 Mortality Mortality Mortality 2 Years DES nN	nN 0 / 58 0 / 38 0 / 38 0 / 30 0 / 264 8 2 / 118 4 / 525 6 / 643 3 5 5 6 / 907 5 5	Favours DES Favours Ster	ts Weight \rightarrow 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 ts Weight %	(95%CI Fixed) 1.49[0.06,37.23] 0.79[0.03,19.08] 12.34[0.68,225,38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56] 1.49[0.52,4.19] 2.05[0.87,4.84] OR (95%CI Fixed)
Test for overall ef Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtota(95%CI) Test for heteroger Test for overall ef O2 Rapamycin DES RAVEL Subtota(95%CI) Test for overall ef Total(95%CI) Test for overall ef Comparison: Outcome: Study 02 Rapamycin DES RAVEL Cicl*	Mortality Mortality: 12 months DES n.N 1/118 1/152 5/128 0/30 7/428 ret z=1.56 p=0.12 5 2/120 7/533 9/653 ret z=0.74 p=0.5 16/1081 ret z=0.74 p=0.5 16/1081 ret z=1.63 p=0.10 Mortality Mortality: 2 Years DES n.N 5 6/120	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118	Favours DES Favours Ster	ts Weight \rightarrow 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 ts Weight % - 100.0	(95%CI Fixed) 1.49(0.06.37.23) 0.76(0.03.19.08) 1.2.34(0.68,225.36) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 0R (95%CI Fixed) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUSI Subtota(65%C) Test for heteroger Test for overall ef 02 Rapamycin DES RAVEL SiRIUS VCC Subtota(65%C) Test for heteroger Test for overall ef Total(95%C) Test for heteroger Test for overall ef Comparison: Outcome: Study 02 Rapamycin DES RAVEL VCC'	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 etty chi-square=191 df-2 p=0.3 tect z=1.56 p=0.12 5 2/120 7/533 9/653 9/653 9/653 9/653 16/1081 etty chi-square=2.37 df=4 p=0.6 tect z=1.63 p=0.10 Mortality Mortality Mortality 2 feas DES nN 6/120 6/120	nN 0 / 58 0 / 38 0 / 38 0 / 30 0 / 264 8 2 / 118 4 / 525 6 / 643 3 5 5 6 / 907 5 5	Favours DES Favours Ster	ts Weight \rightarrow 8.4 → 10.0 → 5.9 0.0 → 24.3 25.2 50.5 75.7 100.0 10 ts Weight %	(95%CI Fixed) 1.49[0.06,37.23] 0.79[0.03,19.08] 12.34[0.68,225,38] Not Estimable 3.81[0.71,20.38] 0.98[0.14,7.10] 1.73[0.50,5.56] 1.49[0.52,4.19] 2.05[0.87,4.84] OR (95%CI Fixed)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotal(95%CI) Test for heteroger Test for overall ef 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotal(95%CI) Test for heteroger Test for overall ef Total(95%CI) Test for heteroger Test for overall ef Comparison: Outcome: Study 02 Rapamycin DES RAVEL *CIC* Subtotal(95%CI) Test for heteroger Test for heteroger Test for heteroger Subtotal(95%CI) Comparison: Outcome: Study	Mortality Mortality: 12 months DES nM 1/118 1/152 5/128 0/30 7/428 ety 2/120 7/428 ety 2/120 7/428 ety 2/120 7/428 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 8/1081 ety 2/120 fect z=0.74 p=0.5 16/1081 ety 2/120 fect z=1.63 p=0.10 Mortality Mortality: 2 Years DES nM 5 6/120 6/120 6/120 ety chi-square=0.0 df=0	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06.37.23) 0.76(0.03.19.08) 1.2.34(0.68,225.36) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 0R (95%CI Fixed) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotal(95%CI) Test for heteroger Test for noverall ef 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotal(95%CI) Test for neteroger Test for overall ef Total(95%CI) Test for neteroger Test for noverall ef Comparison: Outcome: Study 02 Rapamycin DES RAVEL *CIC* Subtotal(95%CI) Test for neteroger Test for neteroger Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 etty chi-square=191 df-2 p=0.3 tect z=1.56 p=0.12 5 2/120 7/533 9/653 9/653 9/653 9/653 16/1081 etty chi-square=2.37 df=4 p=0.6 tect z=1.63 p=0.10 Mortality Mortality Mortality 2 feas DES nN 6/120 6/120	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 0R (95%CI Fixed) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotal(95%CI) Test for heteroger Test for noverall ef 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotal(95%CI) Test for neteroger Test for overall ef Total(95%CI) Test for neteroger Test for noverall ef Comparison: Outcome: Study 02 Rapamycin DES RAVEL *CIC* Subtotal(95%CI) Test for neteroger Test for neteroger Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger Subtotal(95%CI) Test for neteroger	Mortality Mortality: 12 months DES nM 1/118 1/152 5/128 0/30 7/428 ety 2/120 7/428 ety 2/120 7/428 ety 2/120 7/428 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 ety 2/120 7/533 9/663 8/1081 ety 2/120 fect z=0.74 p=0.5 16/1081 ety 2/120 fect z=1.63 p=0.10 Mortality Mortality: 2 Years DES nM 5 6/120 6/120 6/120 ety chi-square=0.0 df=0	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 0R (95%CI Fixed) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study OI Taxane DES ASPECT ELUTES SCORE × TAXUSI Subtota(95%C) Test for heteroger Test for overall ef O2 Repemycin DES RAVEL SIRIUS YCIC Subtota(95%C) Test for heteroger Test for overall ef Comparison: Outcome: Study O2 Repemycin DES RAVEL SIRIUS YCIC Test for heteroger Test for overall ef Comparison: Outcome: Study O2 Repemycin DES RAVEL *CIC Subtota(95%C) Test for heteroger Test for overall ef Comparison: Outcome: Study O2 Repemycin DES RAVEL *CIC Subtota(95%C) Test for heteroger Test for overall ef Test for overall ef Test for overall ef	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 weby chi-square=31 df-2 p=0.3 retz z=1.56 p=0.12 s 2/120 7/533 9/653 9/653 9/653 9/653 9/653 16/1081 heby chi-square=0.23 df=1 p=0.6 fect z=0.74 p=0.5 16/1081 Mortality Mortality: 2 Years DES nN 6/120 6/120	nN 0 / 58 0 / 38 0 / 138 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06;37.23) 0.76(0.03;19.08) 12.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 0R (95%CI Fixed) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtota(95%CI) Test for heteroger Test for neteroger Test for neteroger	Mortality Mortality: 12 months DES n.N 1 / 118 1 / 152 5 / 128 0 / 30 7 / 428 nety chi-square=0.3 5 2 / 120 7 / 533 9 / 653 retot z=0.74 p=0.5 5 2 / 120 7 / 533 9 / 653 retot z=0.74 p=0.5 16 / 1081 nety chi-square=0.23 df=1 p=0.6 fect z=0.74 p=0.5 6 / 120 n N 5 6 / 120 nety chi-square=0.0 df=0 6 / 120 6 / 120 7 / 120	nN 0 / 58 0 / 38 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 1.2.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 2.05(0.87,4.84) 2.05(0.47,4.84) 2.02(0.49,8.26) 2.02(0.49,8.26) 2.02(0.49,8.26)
Test for overall ef Comparison: Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I SUbtota(95%CI) Test for heteroger Test for hoteroger Test for hoteroger Test for hoteroger Total(95%CI) Test for hoteroger Test for overall ef Comparison: Outcome: Study OZ Rapamycin DES RAVEL COMParison: Outcome: Study Carapamycin DES RAVEL *CIC* Subtotal(95%CI) Test for hoteroger Test for hoteroger	Mortality Mortality: 12 months DES nN 1/118 1/152 5/128 0/30 7/428 weby chi-square=31 df-2 p=0.3 retz z=1.56 p=0.12 s 2/120 7/533 9/653 9/653 9/653 9/653 9/653 16/1081 heby chi-square=0.23 df=1 p=0.6 fect z=0.74 p=0.5 16/1081 Mortality Mortality: 2 Years DES nN 6/120 6/120	nN 0 / 58 0 / 38 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118 3 / 118	Favours DES Favours Ster	ts Weight % % % % % % % %	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 1.2.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 2.05(0.87,4.84) 2.05(0.47,4.84) 2.02(0.49,8.26) 2.02(0.49,8.26) 2.02(0.49,8.26)
Comparison: Dutcome: tudy 1 Taxane DES ASPECT ELUTES SCORE TAXUS I uubtota(95%CI) 2 Rapamycin DES RAVEL SIRUS *CIC* uubtota(95%CI) est for heteroger est for overall ef comparison: Dutcome: tudy 2 Rapamycin DES RAVEL *CIC* uutota(95%CI) est for heteroger est for overall ef comparison: Dutcome: tudy 2 Rapamycin DES RAVEL *CIC* uutota(95%CI) est for heteroger est for overall ef comparison: Dutcome: tudy	Mortality Mortality: 12 months DES n.N 1 / 118 1 / 152 5 / 128 0 / 30 7 / 428 nety chi-square=0.3 5 2 / 120 7 / 533 9 / 653 retot z=0.56 p=0.12 5 2 / 120 7 / 533 9 / 653 retot z=0.74 p=0.5 16 / 1081 nety chi-square=0.23 df=1 p=0.6 fect z=0.74 p=0.5 6 / 120 n N 5 6 / 120 nety chi-square=0.0 df=0 6 / 120 6 / 120 7 / 12	nN 0 / 58 0 / 38 0 / 138 0 / 200 8 2 / 118 4 / 525 6 / 643 3 5 6 / 907 Stents nN 3 / 118 3 / 118	Favours DES Favours Ster	ts Weight \rightarrow 8.4 → 10.0 \rightarrow 5.9 0.0 \rightarrow 24.3 25.2 50.5 75.7 100.0 10 Weight % Weight % 100.0 100.0 100.0	(95%CI Fixed) 1.49(0.06,37.23) 0.76(0.03,19.08) 1.2.34(0.68,225.38) Not Estimable 3.81(0.71,20.38) 0.98(0.14,7.10) 1.73(0.50,5.36) 1.48(0.52,4.19) 2.05(0.87,4.84) 2.05(0.87,4.84) 2.05(0.47,4.84) 2.02(0.49,8.26) 2.02(0.49,8.26) 2.02(0.49,8.26)



Figure 6C

DES: Meta-analysis of any myocardial infarction

Comparison:							
Outcome:		i infaraction: / to 36 days	Any Reporte	d			
		DES Í n/N	Stents n/N	OR (95%CI Fixed)	Weight	OR (95%Cl Fixed)	
Study		II/N	10/8	(35%CI FIXEU)) %	(35%CI Fixeu)	
01 Taxane DES ASPECT		3/118	1/59		→ 8.5	1.51[0.15,14.87]	
DELIVER		4 / 517	1/512		→ 6.5	3.98[0.44,35.77]	
ELUTES × PATENTCY		1/152 0/24	0/38 0/26	· •	→ 5.2 0.0	0.76[0.03,19.08] Not Estimable	
x TAXUSI		0/24	0/20		0.0	Not Estimable	
Subtotal(95%Cl)		8/842	2/665		20.3	2.12[0.52,8.63]	
Test for heterogene Test for overall effe							
Test for overall effe	501 2-1.05 p-0.	5					
02 Rapamycin DES × FUTURE		0.104					
RAVEL		0/24 3/120	0/12 3/118		0.0	Not Estimable 0.98[0.19,4.97]	
SIRIUS		12/533	8/525		51.7	1.49[0.60,3.67]	
Subtotal(95%Cl) Test for heterogene	eity chi-square=(15/677 119 df=1 n=0.66	11 / 655		- 71.1	1.35[0.62,2.96]	
Test for overall effe							
03 Actinomycin DES	_						
ACTION	2	3/241	1/119		→ 8.7	1.49[0.15,14.45]	
Subtotal(95%Cl)		3/241	1/119		▶ 8.7	1.49[0.15,14.45]	
Test for heterogene Test for overall effe							
	501 Z 0.01 p 0.						
T-1-K05% (2)		26 / 1760	44 / 44 / 20		400.0	4 5210 70 2 041	
Total(95%Cl) Test for heterogene	eity chi-square=1		14/1439		► 100.0	1.52[0.79,2.91]	
Test for overall effe							
				.1 .2 1	5 10		
Comparison:	Mvocardia	Infaraction: /	Anv Reporte	Favours DES	Favours Stent		
Outcome:	MÍ Any: 6 r	nonths					
Study		DES n/N	Stents n/N	OR (95%Cl Fixed)	Weight) %	OR (95%Cl Fixed)	
01 Taxane DES					·	. ,	
ASPECT		3/118	1/59	.	→ 3.2	1.51[0.15,14.87]	
DELIVER (9 mont	ths)	5/517	5/512	·	12.1	0.99[0.28,3.44]	
ELUTES × PATENTCY (9 mc	onths)	2/152 0/24	0/38 0/26	·	→ 1.9 0.0	1.28[0.06,27.20] Not Estimable	
SCORE		19/128	3/138		→ 6.0	7.84[2.26,27.20]	
TAXUS II Subtotal(95%CI)		5/266	14/270		33.1	0.35[0.12,0.99]	
Test for heterogenei		34/1205 4.52 df=4 p=0.0	23/1043 058		► 56.1	1.38[0.81,2.36]	
Test for overall effe							
02 Rapamycin DES ((9 month)						
SIRIUS	(15/533	17 / 525		40.4	0.87[0.43,1.75]	
Subtotal(95%CI) Test for heterogenei	tu obi oquoro-€	15/533 100 df=0 w=0.000	17 / 525		40.4	0.87[0.43,1.75]	
Test for overall effe			501				
03 Actinomycin DES ACTION	S	4 / 241	1/88		→ 3.5	1.47[0.16,13.32]	
Subtotal(95%Cl)		4 / 241	1/88		▶ 3.5	1.47[0.16,13.32]	
Test for heterogenei Test for overall effe							
rest for overall effe	ж 2-0.34 р-0.	r					
Total(95%Cl) Test for heterogenei		53 / 1979 5.09 df=6 p=0.03	41 / 1656 2	-	100.0	1.18[0.78,1.78]	
Test for overall effe							
				.1 .2 1	5 10		
					Favours Stents		
Comparison.	Myocardia		Any Ronarta	ud .			
Comparison: Outcome:	Myocardia MI Any: 12	months					
Outcome:		months DES	Stents	OR	Weight	OR (95%Cl Fixed)	
Outcome: Study		months			Weight) %	OR (95%Cl Fixed)	
Outcome: Study 01 Taxane DES		months DES	Stents	OR) %	(95%Cl Fixed)	
Outcome: Study 01 Taxane DES ASPECT ELUTES		months DES n/N 3/118 2/152	Stents n/N 1 / 58 0 / 38	OR) % → 4.9 → 2.9	(95%Cl Fixed) 1.49[0.15,14.62] 1.28[0.06,27.20]	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE		3 / 118 2 / 152 27 / 128	Stents n/N 1 / 58 0 / 38 4 / 138	OR) % → 4.9 → 2.9 → 11.4	(95%Cl Fixed) 1.49[0.15,14.62] 1.28[0.06,27.20] 8.96[3.04,26.41]	
Outcome: Study 01 Taxane DES ASPECT ELUTES		months DES n/N 3/118 2/152	Stents n/N 1 / 58 0 / 38	OR) % → 4.9 → 2.9	(95%Cl Fixed) 1.49[0.15,14.62] 1.28[0.06,27.20]	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%CI) Test for heterogene	MÎ Any: 12	3 / 118 2 / 152 27 / 128 0 / 30 32 / 428 2.93 df=2 p=0.23	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264	OR) % → 4.9 → 2.9 → 11.4 0.0	(95%Cl Fixed) 1.49[0.15,14.62] 1.28[0.06,27.20] 8.96[3.04,26.41] Not Estimable	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtotal(95%CI)	MÎ Any: 12	3 / 118 2 / 152 27 / 128 0 / 30 32 / 428 2.93 df=2 p=0.23	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264	OR) % → 4.9 → 2.9 → 11.4 0.0	(95%Cl Fixed) 1.49[0.15,14.62] 1.28[0.06,27.20] 8.96[3.04,26.41] Not Estimable	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtrat(95%CL) Test for heterogene Test for overall effe 02 Rapamycin DES	MÍ Any: 12 etty chi-square=2 ect z=3.78 p=0.	months DES n/N 3/118 2/152 27/128 0/30 32/428 9.93 df=2 p=0.23 0002	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73)	
Outcome: Study Of Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota(95%C)) Test for overall effe 02 Rapamycin DES RAVEL	MÍ Any: 12 etty chi-square=2 ect z=3.78 p=0.	months DES n/N 3/118 2/152 27/128 0/30 32/428 930 df2 p=0.23 0002 4/120	Stents n/N 1/58 0/38 4/138 0/30 5/264 5/118	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 → 18.3	(95%CI Fixed) 1.49(0.15,14,62) 1.29(0.06,27,20) 8.96(3.04,26,41) Not Estimable 5.88(2.35,14,73) 0.78(0.20,2.98)	
Outcome: Study 11 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtote((95%C)) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRUS *CIC*	MÍ Any: 12 etty chi-square=2 ect z=3.78 p=0.	months DES n/N 3 / 118 2 / 152 27 / 128 0 / 30 32 / 428 9.93 df=2 p=0.23 0002 4 / 120 16 / 533	Stents n/N 1/58 0/38 4/138 0/30 5/264 5/118 17/525	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 - 18.3 52.4	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.52(0.46,1.85)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotat(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotat(95%CI) Test for heterogene	MÎ Any: 12	months DES n/N 3/118 2/152 27/128 0/30 32/428 93 df=2 p=0.23 00002 4/120 16/533 20/653 00.56 df=1 p=0.82	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 → 18.3	(95%CI Fixed) 1.49(0.15,14,62) 1.29(0.06,27,20) 8.96(3.04,26,41) Not Estimable 5.88(2.35,14,73) 0.78(0.20,2.98)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI) Test for overall effe Test for overall effe RAVEL SIRUS*CIC* Subtotal(95%CI)	MÎ Any: 12	months DES n/N 3/118 2/152 27/128 0/30 32/428 93 df=2 p=0.23 00002 4/120 16/533 20/653 00.56 df=1 p=0.82	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 - 18.3 52.4	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.52(0.46,1.85)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotat(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRIUS *CIC* Subtotat(95%CI) Test for heterogene	MÎ Any: 12	months DES n/N 3/118 2/152 27/128 0/30 32/428 93 df=2 p=0.23 00002 4/120 16/533 20/653 00.56 df=1 p=0.82	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 - 18.3 52.4	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.52(0.46,1.85)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRUS *CIC* Subtotal(95%CI)	Mi Any: 12	months DES n.H 2/152 27/122 27/128 0/30 32/428 .93 dt=2 p=0.23 0002 4/120 16/53 20/653 .05 dt=1 p=0.82 .7 52/1081	Stents n/H 1 / 58 0 / 38 4 / 138 0 / 38 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907	OR) % → 4.9 → 2.9 → 11.4 0.0 ↓ 19.3 - 18.3 52.4	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.52(0.46,1.85)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Test for heterogene Test for heterogene SIRUS *(C) Subtoli(95%C) Total(95%C) Total(95%C) Total(95%C)	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/	Months DEs nAl 3/118 2/152 27/128 0/30 33 df22 93 df22 93 df22 16/533 20/653 005 df1 005 df1 52/1081 3.71 df4 p=0.00	Stents n/H 1 / 58 0 / 38 4 / 138 0 / 38 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907	OR) % → 4.9 2.9 11.4 0.0 ↓ 19.3 	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.48,1.65)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtotal(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRUS *CIC* Subtotal(95%CI)	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/	Months DEs nAl 3/118 2/152 27/128 0/30 33 df2 p=0.23 0002 4/120 16/533 20/653 005 df=1 p=0.82 7 52/1081 3.71 df=4 p=0.01	Stents n/H 1 / 58 0 / 38 4 / 138 0 / 38 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 52.4 80.7 - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.48,1.65)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS SCORE v TAXUS Test for heterogene Test for heterogene SIRUS *CC* Subtola(95%C) Total(95%C) Total(95%C) Total(95%C)	Mi Any: 12 ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/	Months DEs nAl 3/118 2/152 27/128 0/30 33/418 2/152 27/128 0/30 32/428 33/412 930/42 930/42 0002 4/120 16/533 20/653 005/df=1 p=0.82 .7 52/1081 3.71 df=4 p=0.00 010	Stents NN 1 / 58 0 / 38 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 22 / 643 27 / 907 083	OR (95%CIFixed)) % → 4.9 2.9 11.4 0.0 ↓ 19.3 	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.48,1.65)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtota(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRUS CIC ^A Subtota(95%CI) Test for heterogene Test for overall effe Total(95%CI) Test for heterogene Test for overall effe Comparison:	Mi Any: 12 sty chi-square=2 ct z=3.76 p=0. ety chi-square=(ct z=-0.36 p=0 ety chi-square=(ety	Months DES n/H 3/118 2/152 27/122 0/30 32/428 293 df=2 p=0.23 0002 4/120 16/533 20/653 0.05 df=1 p=0.82 7 52/1081 3.71 df=4 p=0.01 010	Stents NN 1 / 58 0 / 38 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 22 / 643 27 / 907 083	OR (95%CIFixed)) % → 49 29 → 114 00 19.3 - 18.3 62.4 80.7 - 100.0 6 10	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.48,1.65)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtota(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL Subtota(95%CI) Test for heterogene Test for overall effe Total(95%CI) Test for heterogene Test for overall effe Comparison: Outcome:	Mi Any: 12 ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/ ety chi-square=/	Months DES nN 3/118 2/152 27/122 0/30 32/428 330 dfe2 p=0.23 0002 4/120 16/533 20/653 0.05 df=1 p=0.82 7 52/1081 3.71 df=4 p=0.01 010 Infaraction: J DES	Stents n/N 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 083 27 / 907 083	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 19.3 - 18.3 62.4 80.7 - 100.0 Favours Stents Weight	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.48,1.65) 1.85(1.16,2.96) 0.82(1.16,2.96)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS I Subtota(95%CI) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SIRUS CIC ^A Subtota(95%CI) Test for heterogene Test for overall effe Total(95%CI) Test for heterogene Test for overall effe Comparison:	Mi Any: 12 sty chi-square=2 ct z=3.76 p=0. ety chi-square=(ct z=-0.36 p=0 ety chi-square=(ety	months DES nN 3/118 2/152 27/128 0/30 32/428 93 df=2 p=0.23 0002 4/120 16/533 20/653 005 df=1 p=0.82 7 52/1081 3.71 df=4 p=0.00 10 Infaraction: / rears	Stents n/N 1/58 0/38 4/130 5/264 5/118 17/525 22/643 27/907 083 27/907	OR (95%CIFixed)) % → 4.9 2.9 11.4 0.0 19.3 19.3 - 18.3 62.4 80.7 - 100.0 Favours Stents Weight	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.32(0.46,1.85) 0.89(0.48,1.65) 1.85(1.16,2.96)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE X TAXUS1 Tast for heterogene Test for heterogene Total(95%CI) Test for heterogene Test for overall effe Total(95%CI) Test for heterogene Test for overall effe Comparison: Study 02 Rapamycin DES Study 02 Rapamycin DES	Mi Any: 12 sty chi-square=2 ct z=3.76 p=0. ety chi-square=2 ct z=-0.36 p=0 sty chi-square=2 ct z=2.58 p=0. Myocardia Mi Any: 2 y	months DES nN 3/118 2/152 27/128 0/30 32/428 93 df=2 p=0.23 0002 4/120 16/533 20/653 0.05 df=1 p=0.82 .7 52/1081 3.71 df=4 p=0.00 10 Infaraction: J Pears DES nN	Stents n/N 1/58 0/38 4/138 0/30 5/264 5/118 17/525 22/643 27/907 083 27/907 083 27/907 083	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 Favours Stents Weight	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.32(0.46,1.85) 0.89(0.48,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8	
Outcome: Study 01 Taxane DES ASPECT ELUTES ELUTES SCORE × TAXUS1 Subtotia((95%C)) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL Subtota((95%C)) Test for heterogene Total(95%C) Test for heterogene Total(95%C) Test for heterogene Total(95%C) 20 Rapamycin DES RAVEL Study 02 Rapamycin DES RAVEL *CC*	Mi Any: 12 sty chi-square=2 ct z=3.76 p=0. ety chi-square=2 ct z=-0.36 p=0 sty chi-square=2 ct z=2.58 p=0. Myocardia Mi Any: 2 y	months DES n.N 3/118 2/152 27/128 0/30 32/428 330 dt=2 p=0.23 00002 4/120 16/533 20/653 20/653 0.05 dt=1 p=0.82 7 52/1081 3.71 dt=4 p=0.01 010 IInfaraction: / rears n.N 5/120	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 823 27 / 907 843 5tents nN 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - Weight % - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.81(0.24,2.74)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotiq(85%C) Test for heterogene Test for heterogene Test for heterogene Test for heterogene Test for heterogene Test for neterogene Test for neterogene Study 02 Rapamycin DES RAVEL *CIC* Subtotiq(%5%C) Test for heterogene	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/	Months DES n.N 3/118 2/152 27/128 0/30 32/428 33 df=2 p=0.23 00002 4/120 16/533 20/653 0.07 5/1081 3.71 df=4 p=0.00 010	Stents n/N 1/58 0/38 4/138 0/30 5/264 5/118 17/525 22/643 27/907 083 27/907 083 27/907 083	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 Favours Stents Weight	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.32(0.46,1.85) 0.89(0.48,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS I Subtota((95%C)) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL SUbtota((95%C)) Test for heterogene Test for overall effe Total(95%C) Total(95%C) Total(95%C) Comparison: Outcome: Study 02 Rapamycin DES RAVEL *CIC* Subtota(95%C)	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/	Months DES n.N 3/118 2/152 27/128 0/30 32/428 33 df=2 p=0.23 00002 4/120 16/533 20/653 0.07 5/1081 3.71 df=4 p=0.00 010	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 823 27 / 907 843 5tents nN 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - Weight % - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.81(0.24,2.74)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotiq(85%C) Test for heterogene Test for heterogene Test for heterogene Test for heterogene Test for heterogene Test for neterogene Test for neterogene Study 02 Rapamycin DES RAVEL *CIC* Subtotiq(%5%C) Test for heterogene	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/	Months DES n.N 3/118 2/152 27/128 0/30 32/428 33 df=2 p=0.23 00002 4/120 16/533 20/653 0.07 5/1081 3.71 df=4 p=0.00 010	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 823 27 / 907 843 5tents nN 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - Weight % - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.81(0.24,2.74)	
Outcome: Study Of Taxane DES Aspect Aspect ELUTES SCORE X TAXUS Test for heterogene Test for overall effe O2 Rapamycin DES RAVEL Study Total(95%C) Test for heterogene Total(95%C) Comparison: Study O2 Rapamycin DES RAVEL CC Study O2 Rapamycin DES RAVEL CC Study D2 Rapamycin DES RAVEL CC Study D3 Rapamycin DES RAVEL CC Study D4 Rapamycin DES RAVEL CC Study D5 Rapamycin DES RAVE CC Study D5 Rapamycin DES RAVE CC Study D5 Rapamycin DES RAVE CC Study St	Mi Any: 12 sty chi-square= ct z=3.76 p=0. sty chi-square= sty chi-square= sty chi-square= Mi Any: 2 y Myocardia Mi Any: 2 y ety chi-square= sty chi-square= Mi Any: 2 y Myocardia Myocard	months DES nM 3/118 2/152 27/122 0/30 32/428 2.33 df=2 p=0.23 0002 4/120 16/533 20/653 20/70	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 823 27 / 907 843 5tents nN 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - Weight % - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 1.85(1.16,2.96) 0.81(0.24,2.74)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotia((95%C)) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL Subtotia((95%C)) Test for neterogene Total(95%C)) 02 Rapamycin DES RAVEL *CIC* Subtotia((95%C)) Test for heterogene Total(95%C)) Test for heterogene Total(95%C))	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/	months DES nN 3/118 2/152 27/128 0/30 32/428 33012 93012 93012 16/533 20/653 20/653 0000 11 27/1081 3.71 3.71 101 11 101 5/120 0.0 5/120 0.0 0.0 5/120 0.0 5/120 0.0 0.0	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 82 27 / 907 83 27 / 907 84 5 / 118 6 / 118 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - 100.0 - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 0.81(0.24,2.74) 0.81(0.24,2.74)	
Outcome: Study Of Taxane DES Aspect Aspect ELUTES SCORE X TAXUS Test for heterogene Test for overall effe O2 Rapamycin DES RAVEL Study Total(95%C) Test for heterogene Total(95%C) Comparison: Study O2 Rapamycin DES RAVEL CC Study O2 Rapamycin DES RAVEL CC Study D2 Rapamycin DES RAVEL CC Study D3 Rapamycin DES RAVEL CC Study D4 Rave CC Study D5 Rave Study D5 R	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/	months DES nN 3/118 2/152 27/128 0/30 32/428 33012 93012 93012 16/533 20/653 20/653 0000 11 27/1081 3.71 3.71 101 11 101 5/120 0.0 5/120 0.0 0.0 5/120 0.0 5/120 0.0 0.0	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 82 27 / 907 83 27 / 907 84 5 / 118 6 / 118 6 / 118	OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - 100.0 - 100.0 - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 0.81(0.24,2.74) 0.81(0.24,2.74)	
Outcome: Study 01 Taxane DES ASPECT ELUTES SCORE × TAXUS1 Subtotig(85%C) Test for heterogene Test for overall effe 02 Rapamycin DES RAVEL Subtotig(85%C) Test for heterogene Total(95%C) 02 Rapamycin DES RAVEL Study 02 Rapamycin DES RAVEL Subtotig(85%C) 102 Rapamycin DES Study 102 Rapamycin DES Study 102 Rapamycin DES Total(95%C) Total(95%C) Total(95%C) Total(95%C)	Mi Any: 12 aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/ Myocardia Mi Any: 2 j aty chi-square=/ aty chi-square=/ aty chi-square=/ aty chi-square=/	months DES nN 3/118 2/152 27/128 0/30 32/428 33012 93012 93012 16/533 20/653 20/653 0000 11 27/1081 3.71 3.71 101 11 101 5/120 0.0 5/120 0.0 0.0 5/120 0.0 5/120 0.0 0.0	Stents nN 1 / 58 0 / 38 4 / 138 0 / 30 5 / 264 5 / 118 17 / 525 22 / 643 27 / 907 82 27 / 907 83 27 / 907 84 5 / 118 6 / 118 6 / 118	OR (95%CI Fixed Favours DES dd OR (95%CI Fixed) % → 4.9 2.9 11.4 0.0 19.3 - 18.3 62.4 80.7 - 100.0 - 100.0 - 100.0 - 100.0 - 100.0	(95%CI Fixed) 1.49(0.15,14.62) 1.28(0.06,27.20) 8.96(3.04,26.41) Not Estimable 5.88(2.35,14.73) 0.78(0.20,2.98) 0.92(0.46,1.85) 0.89(0.46,1.85) 0.89(0.46,1.85) 1.85(1.16,2.96) 0.81(0.24,2.74) 0.81(0.24,2.74)	



Figure 6DDES: Meta-analysis of binary restenosis

DES Sterts OR Weight OR Study nN nN (95%C1 Fixed) % (95%C1 Fixed) 01 Taxane DES ASPECT 9/118 16/59 5.9 0.22(0.09,0.54) ASPECT 9/118 16/59 5.9 0.22(0.09,0.54) EULTES 17/139 7/34 3.0 0.54(0.20,0.42) PATENTCY (9 months) 8/21 6/17 1.2 1.13(0.30,4.28) SCORE 7/104 35/94 1.0 0.12(0.05,0.29) TAXUS I 0/30 3/29 1.0 0.12(0.07,0.32) Studtods(65%Ct) 50 /668 117/496 35.7 0.22(0.15,0.32) Test for heterogenety chi-square=0.18 dr=5 p=0.037 5.7 0.22(0.15,0.32) 5.7 Test for heterogenety chi-square=0.13 dr=2 p=0.017 5.8 0.6 0.01(0.00.022) SIRUS (9 months) 31/348 128/353 4.7 0.17(0.11,0.28) Sutdtota(65%Ct) 37/604 221/1614 61.7 0.12(0.06,0.17) Test for heterogenety chi-square=0.00 dr	Comparison: Outcome:
ASPECT 9/118 16/59 5.9 0.22(0.90.54) ELUTES 17/139 7/34 3.0 0.54(0.20,1.42) PATENTCY (9 months) 8/21 6/17 1.2 1.13(0.30,4.26) SCORE 7/104 35/94 10.3 0.12(0.05,0.29) TAXUS I 0/30 3/29 10.0 0.12(0.05,0.29) TAXUS I 9/256 50/263 13.0 0.12(0.07,0.32) Subtota(95%C) 50 / 686 117/496 35.7 0.22(0.15,0.32) Test for heterogenety ch-square=0.13 df=5 p=0.037 5.8 0.06(0.02.0.14) 5.7 RAVEL 0/105 26/154 18.5 0.06(0.02.0.14) RAVEL 0/105 26/154 16.5 0.010(0.0.0.22) SiRtUS (9 months) 31/348 128/353 4 0.17(0.11,0.26) Subtota(95%C) 31/42 128/353 5.7 0.22(0.16,0.27) Test for heterogenety ch-square=0.13 df=2 p=0.017 10.12(0.06,0.17) 10.12(0.06,0.17) Test for heterogenety ch-square=0.00 df=0 p=0.00001 2.6 2.17(0.93,5.07) Subtota(95%C) 49/228 7/64	Study
ELUTES 17/139 7/34 30 0.54(0.20;1.42) PATENTCY (9 months) 8/21 6/17 12 1.13(0.30;4.26) SCORE 7/104 35/94 10 0.12(0.05;0.29) TAXUS1 0/30 3/29 10 0.12(0.05;0.29) TAXUS1 0/30 3/29 14.3 0.18(0.05;0.29) TAXUS1 0/30 3/29 14.3 0.18(0.05;0.29) TAXUS1 0/30 50/668 117/496 35.7 0.22(0.15,0.32) Test for heterogeneity chi-square=11.81 df=5 p=0.037 165 15.3 16.5 16.5 SRUS C(C* 6/151 65/154 65/154 18.5 0.06(0.02,0.14) 17.44 RAXPEL 0/105 28/107 34.7 0.17(0.110,26) 34.7 0.17(0.10,26) Skutotar(6%sC) 37/604 221/614 4 61.7 0.12(0.08,0.17) 17.11.36 16.7 0.12(0.08,0.17) Test for heterogeneity chi-square=0.00 f1/64 2.6 2.17(0.93,5.07) 2.6 2.17(0.93,5.07) Subtotar(95%C) 135/1500 345/1174 100.	01 Taxane DES
PATENTCY (9 months) 8 / 21 6 / 17 1.2 1 13[0.30,4.26] ScORE 7 / 104 35 / 94 10.3 0.12[0.05,0.28] TAXUS I 9 / 256 50 / 263 10.0 0.12[0.05,0.28] TAXUS I 9 / 256 50 / 263 10.0 0.12[0.01,251] TAXUS I 9 / 256 50 / 263 14.3 0.16[0.07,0.52] Subtotal(5%C) 50 / 668 117 / 496 35.7 0.22[0.15,0.32] Test for heterogeneity chi-square=11.81 cfr-5 p=0.037 57.0 0.22[0.15,0.32] 57.0 0.22[0.15,0.32] Test for heterogeneity chi-square=0.13 65 / 154 6.7 8.4 0.01[0.00,0.22] SiRUS (9 months) 31 / 348 128 / 353 34.7 0.17[0.11,0.26] Subtotal(6%C) 37 / 604 221 / 614 61.7 0.12[0.06,0.17] Test for heterogeneity chi-square=0.00 df=0 p=0.00001 77.64 2.6 2.17[0.93,5.07] Subtotal(6%%C) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p=0.0001 100.0 0.21[0.16,0.26] 100.0	ASPECT
SCORE 7/104 35/94 10.3 0.12(0.05,0.29) TAXUS I 0/30 3/29 10.3 0.12(0.05,0.29) TAXUS I 9/256 50/263 14.3 0.16(0.07,0.32) Subtotate(95%C) 50/268 117/496 35.7 0.22(0.15,0.32) Test for heterogeneity chi-square=0.18 116/5 p=0.037 35.7 0.22(0.15,0.32) Test for heterogeneity chi-square=0.13 65/151 65/154 18.5 0.06(0.02,0.14) RAVEL 0/105 28/107 84 0.01(0.00,0.22) SRIUS (9 monthe) 31/246 128/353 47 0.17(0.11,0.26) Subtotate(95%Cr) 37/604 221/614 61.7 0.12(0.08,0.17) 61.7 0.12(0.08,0.17) Test for heterogeneity chi-square=0.00 d1=0 7/64 2.6 2.17(0.93,5.07) Subtotate(95%Cr) 49/228 7/64 2.6 2.17(0.93,5.07) Test for heterogeneity chi-square=0.00 d1=0 p=0.00001 45/1174 100.0 0.21[0.16,0.26]	ELUTES
TAXUS1 0/30 3/29 TAXUS1 9/256 50/263 Subtots(6%C) 50/663 117/456 Test for heterogenety chi-square=1.81 df-5 p=0.037 Test for heterogenety chi-square=1.81 df-5 p=0.037 Test for heterogenety chi-square=1.81 df-5 p=0.037 Test for heterogenety chi-square=0.13 df-2 p=0.017 SiRUS (9 months) 31/348 128/33 Subtots(95%C) 37/604 221/614 61.7 0.120.08,0.17] Test for heterogenety chi-square=0.00 df=0 p=0.00001 03 Actinomycin DES ACTION 48/228 ACTION 48/228 7/64 Subtots(95%C) 135/1500 345/1174 400.0 02 Actinomycin DES ACTION 48/228 ACTION 48/228 7/64 2.6 2.17(0.93,5.07] Test for heterogenety chi-square=0.00 df=0 p=0.00001 Test for heterogenety chi-square=54.48 df=9 p=0.0001	PATENTCY (9 m
TAVUS I 9/256 50/283 Subtote(95%C) 50/688 117/496 Test for heterogeneity chi-square=11.81 d+5 p=0.037 Test for heterogeneity chi-square=0.13 65/154 E-SRIUS (9 months) 31/248 128/353 35.7 0.16[0.07.0.32] Subtote(95%C) 6/151 65/105 28/107 E-SRIUS (9 months) 31/248 128/353 34.7 0.17[0.11,0.26] Subtote(95%C) 37/604 221/614 61.7 012 (0.00.01 03 Actinomycin DES Action Veh-square=0.13 d+2 p=0.017 Test for heterogeneity chi-square=0.00 d+0 p=0.00001 03 Actinomycin DES Action Veh-square=0.00 d+0 p=0.00001 Test for heterogeneity chi-square=0.00 d+0 p=0.00001 Test for heterogeneity chi-square=0.00 d+0 p=0.00001 Test for heterogeneity chi-square=0.00 d+0 p=0.00001 Test for heterogeneity chi-square=54.48 d+9 p=0.00001	SCORE
Subtota(95%C) 50 / 688 117 / 496 35.7 0.22[0.15[0.32] Test for vergeneity chi-square=11.81 df=5 p=0.037 1df=5 p=0.037 1df=5 p=0.037 1df=5 p=0.037 20 Repartycin DES E-SIRUS YCIC* 6 / 151 65 / 154 18.5 0.06[0.02,0.14] RAVEL 0 / 105 28 / 107 44 18.5 0.07[0.00,0.22] SIRUS (9 months) 31 / 348 128 / 33 34.7 0.17[0.10,26] Subtotat(6%scC) 37 / 604 221 / 614 61.7 0.12[0.08,0.17] Test for overall effect z=-1.1.36 p=0.00001 48 / 228 7 / 64 2.6 2.17[0.93,5.07] Subtotat(95%C) 48 / 228 7 / 64 2.6 2.17[0.93,5.07] Test for heterogeneity chi-square=0.00 df=10 p=0.00001 26 2.17[0.93,5.07] 2.6 Total(95%C) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26]	TAXUS I
Test for heterogenety chi-square=11 81 dr-5 p=0.037 Test for overall effect z=-7.63 p=0.00001 02 Repartych DES E-SRUS (S months) 31 / 348 SIRUS (3 months) 31 / 348 31 / 348 128 / 353 Subtrota(6%C) 37 / 604 221 / 614 61.7 0.17 (0.11,0.28) Subtrota(6%C) 37 / 604 0.3 Actinomycin DES ACTION 48 / 228 7 / 64 Subtrota(6%SC) 48 / 228 7 / 64 Test for overall effect z=-17.3 p=0.007 Test for heterogenety chi-square=0.00 dr=0 p=0.00001 Test for heterogenety chi-square=54.48 dr=9 p=0.00001	TAXUS II
Test for overall effect z=-7.69 p=0.00001 02 Repanycin DES E-SRUIS YCC* 6 / 151 B-SRUIS YCC* 6 / 151 03 Retromycin DES SRUUS (g monthe) 31 / 348 128 / 353 SRUUS (g monthe) 31 / 348 128 / 353 SRUUS (g monthe) 31 / 348 128 / 353 Studtoal(g/SKC) 37 / 604 21 / 614 61.7 0.12[0.08,0.17] Test for heterogeneity chi-square=0.13 df=2 p=0.017 Test for heterogeneity chi-square=0.00 df=0 p=0.00001 Test for heterogeneity chi-square=54.48 df=9 p=0.00001	Subtotal(95%Cl)
02 Repartycin DES E-SRUS YCC* 6 / 151 65 / 154 RAVEL 0 / 105 28 / 107 SIRUS (9 months) 31 / 344 128 / 353 Subtotal(95%C) 37 / 604 221 / 614 Test for heterogenety chi-square=0.13 dr-2 p=0.017 61.7 0.17[0.10.26] 03 Actinomycin DES ACTION 49 / 228 7 / 64 ACTION 49 / 228 7 / 64 2.6 2.17[0.93,5.07] Subtotal(95%C) 43 / 128 / 328 7 / 64 2.6 2.17[0.93,5.07] Test for overall effect z=1 /79 p=0.07 7 / 64 2.6 2.17[0.93,5.07] Total(95%C) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26]	
E-SRUS CIC* 6 / 151 65 / 154 ← 18.5 0.00[0.02,0.14] RAVEL 0 / 105 28 / 107 6.4 0.01[0.00,0.22] SRUS (9 months) 31 / 348 128 / 333 34.7 0.17[0.11,026] Subtotal(95%CC) 37 / 604 221 / 614 61.7 0.12[0.08,0.17] Test for heterogenety cit-square=0.10 d1=2 p=0.017 61.7 0.12[0.08,0.17] 03 Actinomycin DES ACTION 48 / 228 7 / 64 ACTION 48 / 228 7 / 64 2.6 2.17[0.93,5.07] Subtotal(95%CC) 135 / 1500 345 / 1174 ◆ 100.0 0.21[0.16,0.26] Total(95%CC) 135 / 1500 345 / 1174 ◆ 100.0 0.21[0.16,0.26]	Test for overall effe
RAVEL 0/105 28/107 SIRUS (9 months) 31 / 348 128 / 353 SIRUS (9 months) 31 / 348 128 / 353 SIRUS (9 months) 31 / 604 221 / 814 Galaxies 61.7 0.17[0.11,0.26] Subtotal(95%C) 37 / 604 221 / 814 Test for overall effect z=-11.36 p 7 / 64 Subtotal(95%C) 48 / 228 7 / 64 Subtotal(95%C) 48 / 228 7 / 64 Test for heterogenety chi-square=0.00 df=0 p<0.00001	
SIRUUS (9 months) 31 / 348 128 / 353 34.7 0.17[0.11,0.26] Subtota(95%C) 37 / 604 221 / 614 61.7 0.12[0.06,0.17] Test for heterogeneity chi-square=0.13 dr=2 p=0.017 61.7 0.12[0.08,0.17] 03 Actinomycin DES ACTION 48 / 228 7 / 64 2.6 2.17[0.93,5.07] Subtota(95%C) 48 / 228 7 / 64 2.6 2.17[0.93,5.07] Test for heterogeneity chi-square=0.00 dr=0 p=0.00001 7 / 64 2.6 2.17[0.93,5.07] Total(95%C) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26] Total(95%C) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26]	E-SIRIUS *CIC*
Subtotal(95%C) 37 / 604 221 / 614 61.7 0.12[0.08],0.17] Test for versal effect z=1.136 p=0.00001 03 Actinomycin DES 61.7 0.12[0.08],0.17] O3 Actinomycin DES ACTION 49 / 228 7 / 64 2.6 2.17[0.93],5.07] Test for overall effect z=1.78 p=0.001 Total(95%C) 135 / 1500 345 / 1174 100.0 0.21[0.16],0.26]	
Test for heterogeneity chi-square=8.13 df=2 p=0.017 Test for overall effect z=-11.36 p=0.00001 03 Actinomycin DES ACTION 48 / 228 7 / 64 Subtroling(5%CC) 48 / 228 7 / 64 Test for heterogeneity chi-square=0.00 df=0 p=0.00001 2.6 2.17[0.93,5.07] Test for heterogeneity chi-square=0.00 df=0 p=0.00001 2.6 2.17[0.93,5.07] Total(95%CC) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p=0.00001 100.0 0.21[0.16,0.26]	
Test for overall effect z=-11.36 p<0.00001	
03 Actinomycin DES A.CTION 48 / 228 7 / 64 Subtrate(8%%C) 48 / 228 7 / 64 Test for heterogeneity chi-square=0.00 df=0 p<0.00001 Total (95%C1) 135 / 1500 345 / 1174 ← 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p<0.00001	
A CTION 48 / 228 7 / 64 2.6 2.17(0.93,5.07) Subtotal(95%CI) 48 / 228 7 / 64 2.6 2.17(0.93,5.07) Test for heterogeneity chi-square=0.00 df=0 p=0.00001 Test for overall effect z=1.79 p=0.07 Total(95%CI) 135 / 1500 345 / 1174 ← 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p=0.00001	Test for overall effe
Subtotal(95%Cl) 48 / 228 7 / 64 2.6 2.17[0.93],5.07] Test for heterogeneity chi-square=0.00 df=0 p=0.00001 2.6 2.17[0.93],5.07] Test for overall effect z=1.79 p=0.07 2.6 2.17[0.93],5.07] Total(95%Cl) 135 / 1500 345 / 1174 4 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=5 p=0.00001 4 100.0 0.21[0.16,0.26]	
Test for heterogeneity chi-square=0.00 df=0 p<0.00001 Test for overall effect z=1.79 p=0.07 Total(95%Cl) 135 / 1500 345 / 1174 ← 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p<0.00001	
Test for overall effect z=1.79 p=0.07 Total(95%Cf) 135 / 1500 345 / 1174 ← 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p=0.00001	
Total(95%Cl) 135 / 1500 345 / 1174 100.0 0.21[0.16,0.26] Test for heterogeneity chi-square=54.48 df=9 p<0.00001	
Test for heterogeneity chi-square=54.48 df=9 p<0.00001	Test for overall effe
Test for heterogeneity chi-square=54.48 df=9 p<0.00001	Totok(95% CD
Test for overall effect z=-13.20 p<0.00001	
.1 2 1 5 10 Favours CABG Favours Stents	

CIC Information formerly Commercial in Confidence

Figure 6E DES: Meta-analysis of event rate – random effects

Outcome: Event R	DES	Random Effects Stents	OR	Weight	OR	
Study	n/N	n/N	(95%Cl Random)	%	(95%Cl Random)	
01 Taxane DES						
ASPECT	12/118	3/59		10.6	2.11[0.57,7.80]	
ELUTES	9/152	4/38	-	11.1	0.53[0.16,1.84]	
PATENTCY (9 months)	3/24	6/26 —		9.2	0.48[0.10,2.17]	
TAXUSI	0/31	2/30 ←	•	3.5	0.18[0.01,3.93]	
TAXUS II	21 / 266	52 / 270	_ - _	16.8	0.36[0.21,0.62]	
Subtotal(95%CI)	45 / 591	67 / 423		51.2	0.55[0.27,1.10]	
Test for heterogeneity chi-squa	re=6.46 df=4 p=0.	17				
Test for overall effect z=-1.69	p=0.09					
02 Rapamycin DES (9 month)						
E-SIRIUS *CIC*	14/175	40 / 177	_ -	15.9	0.30[0.16,0.57]	
SIRIUS	38 / 533	99 / 525	_ 	17.8	0.33[0.22,0.49]	
Subtotal(95%Cl)	52 / 708	139 / 702	+	33.7	0.32[0.23,0.45]	
Test for heterogeneity chi-squa	re=0.07 df=1 p=0.	79				
Test for overall effect z=-6.58	p<0.00001					
03 Actinomycin DES						
ACTION	56 / 241	9/88	_	- 15.1	2.66[1.25,5.63]	
Subtotal(95%Cl)	56 / 241	9/88		► 15.1	2.66[1.25,5.63]	
Test for heterogeneity chi-squa	re=0.00 df=0 p<0.	00001				
Test for overall effect z=2.55	p=0.01					
T-1-K059(c))	452 / 4540	245 (4242		400.0	0.000.04.4.441	
Total(95%Cl) Test for heterogeneity chi-squa	153/1540	215/1213		100.0	0.59[0.31,1.11]	
Test for neterogeneity cni-squa Test for overall effect z=-1.64		1.00001				
rest for overall effect Z=-1.64	p=0.10					
		.1	2 1 5	10		

CIC Information formerly Commercial in Confidence

